AllerFund Ventures

AllerFund Ventures, established in 2020 and based in Scarsdale, New York, is a venture capital firm focused on creating social impact for the food allergy community. The firm aims to accelerate the development and commercialization of innovative treatments, diagnostics, and products for individuals with food allergies, particularly children and those at risk. AllerFund invests in early-stage companies across various sectors, including biopharma, medical devices, diagnostics, and consumer products, with the goal of facilitating breakthroughs that can lead to cures and significantly enhance the quality of life for affected individuals.

Eric Rosenkranz

Partner

Lisa Strovink

Managing Partner

Liza Shapiro Strovink

Managing Partner

4 past transactions

IgGenix

Series B in 2023
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Alladapt Immunotherapeutics

Venture Round in 2022
Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

IgGenix

Series A in 2021
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Amulet

Seed Round in 2020
Allergy Amulet Inc. is a Madison, Wisconsin-based company founded in 2016 that specializes in the manufacturing and sale of consumer food allergen sensors. Its flagship product, the Allergy Amulet, is recognized as the world's smallest and fastest device for testing food for common allergens, providing results in seconds. Designed for portability, it can be conveniently carried on a keychain, necklace, or wristband, allowing users to maintain safety while enjoying meals. With food allergies affecting approximately 32 million Americans and millions more worldwide, Allergy Amulet aims to enhance the quality of life for individuals with food allergies or intolerances. The company serves a diverse clientele, including families, individuals, and businesses, addressing the critical need for rapid allergen detection in everyday situations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.